Lupin Limited has informed the Exchange regarding a press release dated December 17, 2025, titled "Lupin Receives Positive CHMP Opinion for Biosimilar Ranibizumab".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has shared a press release about receiving a positive opinion from the European Medicines Agency's CHMP (Committee for Medicinal Products for Human Use) for its biosimilar Ranibizumab. Ranibizumab is a biologic medicine typically used to treat eye conditions like wet age-related macular degeneration. A positive CHMP opinion is a key regulatory step, usually leading to formal European Union marketing authorisation within a few months. This strengthens Lupin's presence in the biosimilars space and opens up the European market for the product.
This is a positive development for Lupin, signalling progress in its high-value biosimilars pipeline and potential entry into the lucrative European market, which could support future revenue growth.